CN102665700A - 治疗实体瘤和其它恶性肿瘤的方法和组合物 - Google Patents

治疗实体瘤和其它恶性肿瘤的方法和组合物 Download PDF

Info

Publication number
CN102665700A
CN102665700A CN2010800517592A CN201080051759A CN102665700A CN 102665700 A CN102665700 A CN 102665700A CN 2010800517592 A CN2010800517592 A CN 2010800517592A CN 201080051759 A CN201080051759 A CN 201080051759A CN 102665700 A CN102665700 A CN 102665700A
Authority
CN
China
Prior art keywords
alkyl
alkoxy
halo
methyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800517592A
Other languages
English (en)
Chinese (zh)
Inventor
S·博纳米奇
M·多施
C·加西亚-埃切维里亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43384585&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102665700(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102665700A publication Critical patent/CN102665700A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800517592A 2009-11-18 2010-11-17 治疗实体瘤和其它恶性肿瘤的方法和组合物 Pending CN102665700A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26234209P 2009-11-18 2009-11-18
US61/262,342 2009-11-18
US29203210P 2010-01-04 2010-01-04
US61/292,032 2010-01-04
PCT/US2010/056942 WO2011062939A1 (en) 2009-11-18 2010-11-17 Methods and compositions for treating solid tumors and other malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410410334.6A Division CN104224791A (zh) 2009-11-18 2010-11-17 治疗实体瘤和其它恶性肿瘤的方法和组合物

Publications (1)

Publication Number Publication Date
CN102665700A true CN102665700A (zh) 2012-09-12

Family

ID=43384585

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800517592A Pending CN102665700A (zh) 2009-11-18 2010-11-17 治疗实体瘤和其它恶性肿瘤的方法和组合物
CN201410410334.6A Pending CN104224791A (zh) 2009-11-18 2010-11-17 治疗实体瘤和其它恶性肿瘤的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410410334.6A Pending CN104224791A (zh) 2009-11-18 2010-11-17 治疗实体瘤和其它恶性肿瘤的方法和组合物

Country Status (18)

Country Link
US (2) US20120232087A1 (https=)
EP (1) EP2501370A1 (https=)
JP (1) JP2013511526A (https=)
KR (1) KR20120107962A (https=)
CN (2) CN102665700A (https=)
AU (1) AU2010322114B2 (https=)
BR (1) BR112012011823A2 (https=)
CA (1) CA2781210A1 (https=)
CL (1) CL2012001271A1 (https=)
IL (1) IL219636A0 (https=)
MA (1) MA33739B1 (https=)
MX (1) MX2012005695A (https=)
NZ (1) NZ599964A (https=)
PH (1) PH12012500911A1 (https=)
RU (1) RU2012125152A (https=)
TN (1) TN2012000205A1 (https=)
WO (1) WO2011062939A1 (https=)
ZA (1) ZA201203325B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524535A (zh) * 2013-10-16 2014-01-22 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2627911T3 (es) 2009-11-18 2017-08-01 Plexxikon, Inc. Derivados de N-[2-fluoro-3-(4-amino-7H-pirrolo[2,3-d]pirimidin-5-carbonil)-fenil]-4-bencenosulfonamida como moduladores de la proteína quinasa Raf para el tratamiento del cáncer
SG194800A1 (en) * 2011-06-02 2013-12-30 Novartis Ag Biomarkers for hedgehog inhibitor therapy
WO2013106812A1 (en) * 2012-01-12 2013-07-18 Board Of Regents, The University Of Texas System Personalized medicine for the prediction of therapy targeting the hedgehog pathway
EP2914253B1 (en) 2012-11-05 2018-01-03 NantBioScience, Inc. Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway
EP3565520B1 (en) 2017-01-06 2026-02-25 Palvella Therapeutics, Inc. Anhydrous compositions of mtor inhibitors and methods of use
DK3786160T3 (da) 2017-10-27 2022-08-22 Boehringer Ingelheim Int Pyridinderivater og terapeutiske anvendelser deraf som trpc6-inhibitorer
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
US20210346385A1 (en) * 2018-09-21 2021-11-11 MSB Holdings, Inc Taste-masked dosage forms

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2009002469A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
WO2009134574A2 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JP5161102B2 (ja) 2005-11-22 2013-03-13 クドス ファーマシューティカルズ リミテッド ｍＴＯＲ阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体
CA2659851C (en) 2006-08-23 2014-02-25 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007131201A2 (en) * 2006-05-05 2007-11-15 Irm Llc Compounds and compositions as hedgehog pathway modulators
CN101437800A (zh) * 2006-05-05 2009-05-20 Irm责任有限公司 作为hedgehog途径调节剂的化合物和组合物
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2008154259A1 (en) * 2007-06-07 2008-12-18 Irm Llc Biphenylcarboxamide derivatives as hedgehog pathway modulators
WO2009002469A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
WO2009112266A1 (en) * 2008-03-12 2009-09-17 Ludwig-Maximilians-Universität Active substance combination with gemcitabine for the treatment of epithelial cancer
WO2009134574A2 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MUELLER ME ET AL: "conbined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer", 《GASTROENTEROLOGY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103524535A (zh) * 2013-10-16 2014-01-22 苏州云轩医药科技有限公司 具有刺猬通路拮抗剂活性的胺基噻唑-吡啶杂环化合物

Also Published As

Publication number Publication date
US20150025074A1 (en) 2015-01-22
NZ599964A (en) 2014-08-29
AU2010322114A1 (en) 2012-05-31
IL219636A0 (en) 2012-07-31
CL2012001271A1 (es) 2012-10-12
RU2012125152A (ru) 2013-12-27
AU2010322114B2 (en) 2014-07-31
CN104224791A (zh) 2014-12-24
BR112012011823A2 (pt) 2019-09-24
EP2501370A1 (en) 2012-09-26
PH12012500911A1 (en) 2012-11-26
KR20120107962A (ko) 2012-10-04
ZA201203325B (en) 2013-01-30
US20120232087A1 (en) 2012-09-13
JP2013511526A (ja) 2013-04-04
MX2012005695A (es) 2012-06-13
CA2781210A1 (en) 2011-05-26
MA33739B1 (fr) 2012-11-01
TN2012000205A1 (en) 2013-12-12
WO2011062939A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CN102665700A (zh) 治疗实体瘤和其它恶性肿瘤的方法和组合物
TWI827646B (zh) Ptpn11抑制劑
ES2789331T3 (es) Inhibidores de TGF-beta
RU2521394C2 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
KR101076943B1 (ko) 헷지호그 경로 조절제로서의 화합물 및 조성물
AU2009299927B2 (en) Smoothened antagonism for the treatment of hedgehog pathway-related disorders
KR101217316B1 (ko) 헷지호그 경로 조절제로서의 바이페닐카르복스아미드 유도체
JP2021528469A (ja) Ｔ細胞アクティベーターとして有用なナフチリジノン化合物
CN105899493A (zh) 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
KR20190117582A (ko) 벤조티오펜 에스트로겐 수용체 조정제
KR20130048293A (ko) 단백질 키나제 억제제로서의 헤테로아릴 화합물 및 조성물
CN116234797A (zh) 用于治疗癌症的tead的杂环抑制剂
US20150209365A1 (en) Methods and Compositions for Treating Luekemia
CN120712263A (zh) 瞬时受体电位香草素6抑制剂
HK40039574B (zh) Ptpn11(shp2)抑制剂
CN116621921A (zh) 酰胺类化合物、其制备方法及其在医药上的应用
JP2025524343A (ja) 新規ｒａｓ阻害剤
CN116925174A (zh) 脲类化合物、其制备方法及其在医药上的应用
IL299251B1 (en) Indole derivatives and uses thereof for treating a cancer
HK40039574A (en) Ptpn11(shp2) inhibitors
HK40037519B (zh) Ptpn11的取代的杂环抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120912